Kazuma Kishi

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer

Toshihiko Satō, Satoshi Teramukai, Haruhiko Kondo et al. · Journal of Thoracic and Cardiovascular Surgery · 2013 · 308 citations · Full text

Acute Lung Injury, Inflammatory Lung Disease, Advanced Lung Disease +12

Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases

Toshihiko Satō, Atsushi Watanabe, Haruhiko Kondo et al. · Journal of Thoracic and Cardiovascular Surgery · 2014 · 150 citations · Full text

Surgical Oncology, Advanced Lung Disease, Medicine +10

Pulmonary Tumor Thrombotic Microangiopathy: A Clinical Analysis of 30 Autopsy Cases

Hironori Uruga, Takeshi Fujii, Atsuko Kurosaki et al. · Internal Medicine · 2013 · 149 citations · Full text